Mesalazine (Asacol, Octasa, Pentasa): Uses and Side Effects

What is Mesalazine?

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate medication used to treat inflammatory bowel disease (IBD). It is structurally related to salicylates and non-steroidal anti-inflammatory drugs, functioning as a potent anti-inflammatory agent. Mesalazine has been a cornerstone of IBD treatment for over three decades and remains the recommended first-line therapy for mild-to-moderate ulcerative colitis according to major clinical guidelines, including those from the European Crohn’s and Colitis Organisation (ECCO) and American Gastroenterological Association (AGA).

The medication is available under various brand names, including Asacol, Octasa, and Pentasa, which differ in their formulation and delivery mechanisms to optimize therapeutic effectiveness.

What Conditions Does Mesalazine Treat?

Mesalazine is indicated for specific gastrointestinal conditions characterized by inflammation:

• Ulcerative Colitis (UC): Mesalazine is approved for treating mild to moderately active ulcerative colitis in adults and children aged 5 years and older. It is also used to maintain remission once achieved in UC patients.
• Crohn’s Disease (Ileocolitis): The medication is used for maintenance of remission in Crohn’s ileocolitis, though its use in induction of Crohn’s disease remission remains controversial. The British Society of Gastroenterology guidelines recommend against mesalazine for induction of remission in Crohn’s disease.

In clinical practice, disease severity is classified as mild-to-moderate, moderate-to-severe, or severe-to-fulminant, with mesalazine being most effective in the milder disease categories.

How Does Mesalazine Work?

The mechanism of action of mesalazine involves multiple anti-inflammatory pathways. Although not fully understood, mesalazine is believed to operate through several key processes:

• Prostaglandin Inhibition: Mesalazine inhibits prostaglandin synthesis by blocking cyclooxygenase pathways in the colon, reducing inflammatory mediator production.
• Leukotriene Interference: The drug interferes with leukotriene synthesis and blocks leukotriene B4 production, which is elevated in inflammatory bowel disease.
• Leukocyte Migration Suppression: Mesalazine inhibits leukocyte chemotaxis, reducing the migration of inflammatory cells to affected tissue.
• Free Radical Scavenging: The medication acts as a potent scavenger of free radicals, protecting intestinal cells from oxidative stress.
• Cytokine Reduction: Mesalazine decreases abnormal cytokine production that contributes to inflammation.

Importantly, mesalazine appears to be active primarily through topical action rather than systemic effects. The drug acts on colonic epithelial cells, is metabolized by intestinal epithelial cells, and is excreted locally, allowing it to maximize therapeutic benefit at the site of inflammation while minimizing systemic absorption.

Dosage and Administration

Mesalazine dosing varies depending on the formulation, disease severity, and individual patient response. Different delivery systems (oral tablets, granules, enemas) allow flexible dosing strategies:

• Standard Dosing: Typical doses range from 2g to 4.8g daily for treating active disease, with maintenance doses often around 2g daily.
• High-Dose Therapy: Studies support the use of higher doses (4.8g/day) in patients with moderately active disease, particularly those with previous treatment exposure. The time to cessation of rectal bleeding was significantly shorter with 4.8g/day compared to 2.4g/day (9 versus 16 days).
• Maintenance Therapy: Following a sustained period of remission, guidelines recommend maintaining an oral dose of at least 2g/day mesalazine to prevent relapse. Longer durations of treatment with mesalazine 4g/day for at least 6 months led to significant reduction in relapse risk.
• Flexible Delivery: Mesalazine can be administered orally as tablets or granules, rectally as enemas, or through a combination of oral and rectal therapies to maximize colonic delivery.

Clinical Efficacy and Evidence

Robust clinical evidence supports mesalazine’s effectiveness in ulcerative colitis management. Multiple Cochrane reviews and meta-analyses confirm its efficacy at inducing and maintaining remission across the spectrum of disease severity. Key evidence includes:

• In patients with moderately active distal disease, the QUARTZ study demonstrated that 75.6% and 82.4% of those treated with oral and/or rectal prolonged-release mesalazine achieved clinical remission at 8 weeks and 12 months, respectively.
• Corresponding endoscopic remission (Mayo endoscopy score <1) was achieved in 57.1% at 8 weeks and 61.5% at 12 months.
• Health-related quality of life significantly improved in patients receiving prolonged-release mesalazine, with Short Inflammatory Bowel Disease Questionnaire scores improving from 35.9 at baseline to 43.3 at week 8.
• The ASCEND III study confirmed clinical benefit of delayed-release mesalamine at 4.8g/day in moderately active UC, with higher improvement in patients who had received previous treatment.

If rectal bleeding has not ceased within 10 days on high-dose mesalazine (>4g), the patient is likely a slow or incomplete responder, warranting treatment escalation at that stage.

Side Effects and Safety Profile

One of mesalazine’s principal advantages is its excellent tolerability profile, which is comparable to placebo. Multiple meta-analyses have reported similar adverse event rates for mesalazine and placebo in randomized controlled trials.

Common Side Effects: The most frequently reported adverse events include:

• Headache
• Nausea
• Abdominal pain
• Nasopharyngitis
• Rash
• Loss of appetite
• Flatulence
• Fever

Notably, these adverse events occur with similar frequency in patients receiving placebo, suggesting they may not be directly attributable to mesalazine itself. Studies have found no clinically relevant difference in adverse event profile or rate between higher (>2g) and lower (<2g) daily doses, which is unusual for medications with documented efficacy.

The minimal adverse event burden is largely attributable to mesalazine’s topical mechanism of action on the intestinal mucosa, limiting systemic absorption and associated toxicities.

Rare but Serious Adverse Events: Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine, though this remains an uncommon complication.

Advantages Over Alternative Treatments

Mesalazine offers several distinct advantages compared to other IBD therapies:

• First-Line Status: Endorsed by major international gastroenterology organizations as first-line therapy for mild-to-moderate UC.
• Tolerability: Superior tolerability compared to corticosteroids and advanced biologic therapies, which carry significant potential for toxicities.
• Long-Term Safety: Established safety profile for long-term use with flexible dosing options.
• Cost-Effectiveness: Generally more affordable than advanced therapies such as biologics.
• Proven Efficacy: Decades of clinical evidence demonstrating effectiveness in both induction and maintenance of remission.

Special Considerations

Use in Crohn’s Disease: While mesalazine is used for maintenance of remission in Crohn’s ileocolitis, its role in induction of Crohn’s disease remission is limited and not recommended by major guidelines, distinguishing it from its use in ulcerative colitis.

Disease Activity Assessment: Clinical response to mesalazine varies by patient subgroup. Those with newly diagnosed disease or those who have relapsed after prolonged remission represent ideal candidates for mesalazine therapy. Assessment of response, particularly by monitoring cessation of rectal bleeding and clinical remission, guides treatment intensification decisions.

Dosing Flexibility: The lack of notable dose-dependent adverse effects allows clinicians to escalate doses as needed without safety concerns, facilitating individualized treatment strategies.

Frequently Asked Questions

Q: How long does it take for mesalazine to work?

A: Mesalazine begins acting locally on the colonic mucosa within days, but clinical improvement typically becomes evident within 1-2 weeks. Some patients may require 6-8 weeks to achieve full therapeutic benefit, particularly in achieving complete endoscopic remission.

Q: Can mesalazine be used during pregnancy?

A: Mesalazine is generally considered safe during pregnancy as a category A medication in most studies, though individual assessment is recommended. Maintaining remission with mesalazine during pregnancy is often preferable to disease flares, which carry their own risks to pregnancy.

Q: What is the difference between Asacol, Octasa, and Pentasa?

A: These brand names represent different formulations with varying delivery mechanisms. Asacol uses pH-dependent release, Octasa employs controlled-release technology, and Pentasa delivers mesalazine gradually throughout the small and large intestine. Selection depends on disease location and individual response.

Q: Can mesalazine be combined with other medications?

A: Yes, mesalazine can be combined with rectal therapies, corticosteroids, or other IBD medications as part of combination therapy. However, individual interactions should be reviewed with healthcare providers.

Q: Is mesalazine effective for maintaining remission long-term?

A: Yes, mesalazine is highly effective for maintenance therapy. Guidelines recommend maintaining treatment with at least 2g/day following remission, with longer durations of 4g/day treatment reducing relapse risk significantly.

Q: What should I do if mesalazine is not working?

A: If clinical improvement is not observed within 10 days of high-dose therapy (>4g/day), treatment escalation with alternative therapies such as corticosteroids or biologics should be considered after evaluation by a gastroenterologist.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb